| Overall N = 712 | LDL-C goal attainment N = 71 | No LDL-C goal attainment N = 641 | p-value |
---|---|---|---|---|
Monotherapy | 476 (66.9) | 43 (60.6) | 433 (67.6) | 0.2 |
Statin | 465 (65.3) | 43 (60.6) | 422 (65.8) | 0.4 |
Fibrate | 4 (0.6) | 0 (0) | 4 (0.6) | 1.0 |
Ezetimibe | 7 (1.0) | 0 (0) | 8 (1.2) | 1.0 |
Combination therapy | 236 (33.1) | 28 (39.4) | 208 (32.4) | 0.2 |
Statin + Ezetimibe | 182 (25.6) | 22 (31.0) | 160 (25.0) | 0.3 |
Statin + Ezetimibe + n3 fatty acids | 24 (3.4) | 2 (2.8) | 22 (3.4) | 1.0 |
Statin + n3 fatty acids | 24 (3.4) | 2 (2.8) | 22 (3.4) | 1.0 |
Other | 6 (0.8) | 2 (2.8) | 4 (0.6) | 0.1 |
% LDL-C reduction efficacy | Â | Â | Â | 0.5 |
low | 42 (5.9) | 4 (5.6) | 38 (5.9) | Â |
moderate | 486 (68.3) | 45 (63.4) | 441 (68.8) | Â |
high | 160 (22.5) | 18 (25.4) | 142 (22.2) | Â |
very high | 24 (3.4) | 4 (5.6) | 20 (3.1) | Â |